Effects of Abdominal Binder on Dysnea, Control Pause and Quality of Life in Asthmatic Patients
21 maggio 2026 aggiornato da: Foundation University Islamabad
This study investigates the effects of using an abdominal binder as an adjunct to diaphragmatic breathing in asthma patients.
The goal is to determine if the binder improves respiratory mechanics, specifically reducing dyspnea ,and increasing breath-hold time (control pause) and quality of life over a four-week period
Panoramica dello studio
Stato
Completato
Condizioni
Descrizione dettagliata
This randomized controlled trial (RCT) investigates the efficacy of an abdominal binder as an adjunct to diaphragmatic breathing in 32 asthma patients (aged 18-60).
Participants are allocated into two groups: the experimental group receives binder-assisted diaphragmatic breathing exercises (14 sessions/week for 4 weeks), while the control group performs conventional diaphragmatic breathing exercises.
The study aims to evaluate improvements in respiratory mechanics, specifically focusing on reducing dyspnea, increasing breath-hold duration (control pause), and enhancing asthma-related quality of life.
The intervention involves applying an external abdominal binder to provide resistance and tactile feedback during diaphragmatic breathing.
Training intensity progresses from light resistance (weeks 1-2) to high resistance (weeks 3-4).
The primary goal is to optimize diaphragmatic excursion and reduce the work of breathing associated with asthmatic hyperinflation.
Tipo di studio
Interventistico
Iscrizione (Effettivo)
32
Fase
- Non applicabile
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
-
Islamabad, Pakistan
- Foundation University Islamabad
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
- Bambino
- Adulto
Accetta volontari sani
No
Descrizione
Inclusion Criteria:
- Age :18 to 65
- Diagnosed asthma (persistent, not solely intermittent, seasonal, or exercise-induced).
- Mild to moderate asthma; > 2 days/week (not daily) Minor activity limitation* FEV₁ ≥80.
- Capable of performing dyspnea control pause (DCP) testing and completing QoL questionnaires.
- No recent hospitalization due to asthma.
Exclusion Criteria:
- Intermittent, seasonal-only, or exercise-induced asthma.
- Presence of other major respiratory diseases (COPD, bronchitis, pneumonia, fibro tic disorders)
- Severe comorbidity: cardiac arrhythmia, CHF, CAD, uncontrolled hypertension/diabetes, renal/hepatic
- Severe asthma (Symptoms all day Frequent night awakenings* FEV₁ <60% predicted.) ▪️ Unable to perform breathing exercises
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Experimental group abdominal binder-assisted diaphragmatic breathing exercises
This group will receive standard medical management for asthma along with abdominal binder-assisted diaphragmatic breathing exercises.
The abdominal binder will be used to provide external resistance and tactile feedback to the diaphragm.
The intervention will be conducted for 4 weeks ( supervised and home-based sessions).
Training intensity will progress from light resistance (Weeks 1-2) to high resistance (Weeks 3-4).
|
Participants perform slow, deep diaphragmatic inhalations and exhalations Mechanism: The abdominal binder is applied to increase intro-abdominal pressure, helping to reposition the flattened diaphragm in asthma patients into a more efficient, dome-like shape (zone of apposition).
Dosage: 4 weeks total; Progression: Intensity is increased by tightening the binder/increasing resistance over the final 2 weeks of the study.
|
|
Comparatore attivo: Control group conventional diaphragmatic breathing exercises
This group will receive standard medical management for asthma and perform conventional diaphragmatic breathing exercises alone without the use of an abdominal binder.
The frequency and duration will match the experimental group (for week for 4 weeks) to control for the effects of the breathing exercises themselves.
|
This group receives standard medical management for asthma and performs conventional diaphragmatic breathing exercises alone. Unlike the experimental group, these exercises are performed without the use of an abdominal binder. Frequency and Duration: The sessions are conducted 14 times per week for a total of 4 weeks. This matches the experimental group's schedule to ensure the results accurately control for the effects of the breathing exercises themselves. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Dyspnea
Lasso di tempo: 04 weeks
|
Dyspnea was assessed using the Dyspnea-12 Questionnaire, a validated self-administered instrument designed to measure the severity of breathlessness.
The questionnaire consists of 12 items that evaluate both the physical and affective components of dyspnea experienced by the participant.
Each item is scored on a 4-point Likert scale ranging from 0 (none) to 3 (severe), with a total score ranging from 0 to 36.
Higher scores indicate greater severity of dyspnea and a greater impact of breathlessness on daily functioning.
The Dyspnea-12 has demonstrated good reliability and validity for assessing multidimensional breathlessness across clinical populations
|
04 weeks
|
|
control pause (Breath- hold time )
Lasso di tempo: 04 weeks
|
Control pause was assessed using the breath-hold time test, a measure commonly used to evaluate breathing pattern efficiency and carbon dioxide tolerance in individuals with Asthma.
Participants were instructed to sit comfortably and breathe normally for several breaths.
At the end of a normal exhalation, they were asked to gently hold their breath by pinching the nose until the first natural urge to breathe was experienced, such as diaphragmatic contraction or mild air hunger.
The breath-hold duration was recorded in seconds using a stopwatch.
Lower control pause values in asthma are often associated with dysfunctional breathing patterns, airway hyperresponsiveness, and poor symptom control, whereas higher values indicate improved respiratory regulation, greater carbon dioxide tolerance, and enhanced breathing efficiency.
|
04 weeks
|
|
Asthma-Related Quality of Life
Lasso di tempo: 04 weeks
|
Asthma-related quality of life was assessed using the Asthma Quality of Life Questionnaire (AQLQ), a validated 32-item questionnaire designed to evaluate the impact of Asthma on daily functioning and well-being.
The questionnaire assesses four domains: symptoms, activity limitation, emotional function, and environmental stimuli.
Each item is scored on a 7-point Likert scale, with total scores ranging from 1 (severely impaired) to 7 (not impaired).
Higher scores indicate better quality of life, reflecting minimal impact of asthma on daily activities and overall well-being, whereas lower scores indicate poorer functional status, greater symptom burden, and significant lifestyle restriction due to asthma.
|
04 weeks
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio (Effettivo)
18 novembre 2025
Completamento primario (Effettivo)
1 maggio 2026
Completamento dello studio (Effettivo)
1 maggio 2026
Date di iscrizione allo studio
Primo inviato
21 maggio 2026
Primo inviato che soddisfa i criteri di controllo qualità
21 maggio 2026
Primo Inserito (Effettivo)
28 maggio 2026
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
28 maggio 2026
Ultimo aggiornamento inviato che soddisfa i criteri QC
21 maggio 2026
Ultimo verificato
1 maggio 2026
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Malattie del sistema immunitario
- Malattie delle vie respiratorie
- Malattie polmonari
- Disturbi respiratori
- Malattie bronchiali
- Malattie polmonari, ostruttive
- Ipersensibilità respiratoria
- Ipersensibilità, immediata
- Ipersensibilità
- Segni e sintomi, respiratori
- Condizioni patologiche, segni e sintomi
- Segni e sintomi
- Asma
- Dispnea
Altri numeri di identificazione dello studio
- FUCP/CTR/2026/07
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
No
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
No
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .